Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1163-1164 (20 May), doi:10.1136/bmj.332.7551.1163
Personalised drug treatment is getting closer but will not replace good clinical judgment
| The first 150 words of the full text of this article appear below. |
Whether ethnicity is an important contributor to the variable outcome of drug treatment is still a matter of debate. Research evidence on such associations is limited in quantity and variable in quality. Too often patients' ethnicity is classified by using poorly defined criteria or an inadequate scientific basis.1 Indeed, both skin colour and self identification of ethnic origin seem to be poorly correlated with molecular genetics, and most genetic variability is found within, rather than among, continental populations.2 In addition, ethnic differences in drug response might originate from cultural or environmental factors.
In a meta-analysis on p 1177 McDowell and colleagues systematically reviewed the literature and summarised consistent findings about ethnicity and adverse drug reactions to cardiovascular drugs.3 They found, among other interesting results, a threefold higher risk of angioedema in black compared to non-black patients when taking angiotensin converting enzyme inhibitors as well as a doubled risk of
Erik Eliasson, associate professor
Karolinska Institutet, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
(erik.eliasson@ki.se)